PharmaCyte Biotech (PMCB) Operating Expenses (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Operating Expenses of $2.5 million for Q2 2026, up 141.03% year-over-year from $1.0 million in Q2 2025, and up 18.56% quarter-over-quarter from $2.1 million in Q1 2026.
PharmaCyte Biotech (PMCB) Operating Expenses (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Operating Expenses for 17 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Expenses rose 141.03% year-over-year to $2.5 million; the TTM figure through Apr 2026 stood at $6.9 million (up 56.58% YoY), while the FY2026 annual figure was $6.9 million, up 56.55% from the prior year.
- Operating Expenses grew to $2.5 million in Q2 2026 per PMCB's latest filing, from $2.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $3.2 million in Q2 2024 and bottomed at $848305.0 in Q3 2025.
- Historically, Operating Expenses has averaged $1.6 million across 5 years, with a median of $1.5 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 250.52% — and 2025, when it plunged 67.09%.
- PharmaCyte Biotech's Operating Expenses stood at $2.3 million in 2022, then tumbled by 39.21% to $1.4 million in 2023, then decreased by 21.53% to $1.1 million in 2024, then gained by 24.41% to $1.4 million in 2025, then surged by 82.5% to $2.5 million in 2026.
- Business Quant data shows PMCB's Operating Expenses at $2.5 million in Q2 2026, $2.1 million in Q1 2026, and $1.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | PharmaCyte Biotech | 4.43 Mn | 4.43 Mn | - | 2.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.51 Mn |
| Jan 31, 2026 | 2.12 Mn |
| Oct 31, 2025 | 1.38 Mn |
| Jul 31, 2025 | 848,305.00 |
| Apr 30, 2025 | 1.04 Mn |
| Jan 31, 2025 | 960,252.00 |
| Oct 31, 2024 | 1.11 Mn |
| Jul 31, 2024 | 1.27 Mn |
| Apr 30, 2024 | 3.17 Mn |
| Jan 31, 2024 | 1.87 Mn |
| Oct 31, 2023 | 1.41 Mn |
| Jul 31, 2023 | 2.08 Mn |
| Apr 30, 2023 | 903,283.00 |
| Jan 31, 2023 | 1.55 Mn |
| Oct 31, 2022 | 2.32 Mn |
| Jul 31, 2022 | 1.68 Mn |
| Apr 30, 2022 | 1.51 Mn |
| Jan 31, 2022 | 856,119.00 |
| Oct 31, 2021 | 1.00 Mn |
| Jul 31, 2021 | 1.02 Mn |